Sellas Life Sciences Group, Inc. (SLS), Monday announced that the company's ongoing Phase 3 Regal clinical trial of Galinpepimut-S in acute myeloid leukemia has received positive feedback from the Independent Data Monitoring Committee or IDMC.
Based on the findings, IDMC expects the interim analysis to occur by the fourth quarter of 2024.
Angelos Stergiou, President and Chief Executive Officer of SELLAS, commented, "The committee's review did not raise any safety or futility concerns, further strengthening our confidence in the potential of GPS as a safe and effective treatment option for AML patients".
Currently, Sellas' stock is moving down 19.45 percent, to $1.20 over the previous close of $1.5 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.